Paclitaxel in germ cell cancer

Area of Science:

• Oncology
• Pharmacology
• Cancer Cell Biology

Background:

• Teratocarcinoma cell lines, including cisplatin-resistant variants, are valuable models for drug sensitivity studies.
• Paclitaxel, cisplatin, and cyclophosphamide are established chemotherapeutic agents with varying efficacy in germ cell tumors.

Purpose of the Study:

• To quantitatively assess the cytotoxicity of paclitaxel, cisplatin, and 4-hydroxyperoxycyclophosphamide against teratocarcinoma cell lines.
• To evaluate the clinical efficacy of paclitaxel as a single agent in previously treated germ cell tumor patients.
• To explore the potential synergistic interactions between these chemotherapeutic agents.

Main Methods:

• In vitro cytotoxicity assays using 833K and 833K/63CP10 teratocarcinoma cell lines.
• A Phase II clinical trial administering paclitaxel (250 mg/m2 via 24-hour infusion) to patients with previously treated germ cell tumors.
• Analysis of response rates in the clinical trial.

Main Results:

• Paclitaxel demonstrated marked cytotoxicity against teratocarcinoma cells, including cisplatin-resistant ones.
• A synergistic cytotoxic effect was suggested for combinations of paclitaxel, cisplatin, and 4-hydroxyperoxycyclophosphamide in vitro.
• In the Phase II trial, 26% (8 of 31) of patients achieved a major response to paclitaxel.

Conclusions:

• Paclitaxel exhibits significant antitumor activity in germ cell tumors, even in pre-treated patients.
• In vitro data suggest potential synergy between paclitaxel, cisplatin, and cyclophosphamide, supporting combination therapy.
• Ongoing studies are investigating paclitaxel-based combination regimens as salvage treatment for germ cell tumors.